Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05643209 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Brugada Syndrome Substrate Characterization and Ablation

Study acronym: UNCOVERBrS
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 15, 2025 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: May 30, 2025 to May 30, 2026 Completion date: Jun 30, 2025 to Jun 30, 2026v5 Show 1 more changeShow less
    • Completion date: Jun 30, 2025 to Jun 30, 2026
  2. Re-verified, no change to tracked fieldsv4
  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Dec 30, 2022 to Feb 1, 2023v3 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 30, 2022 to Feb 1, 2023
  4. Start date: Nov 30, 2022 to Dec 30, 2022v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Independent, single center, prospective study, to evaluate the efficacy, in consecutive BrS patients undergoing catheter ablation, at medium-long term follow-up after epicardial substrate homogenization. The target area is defined collecting signals using high density and high resolution mapping with equi-spaced electrode array. The ablation of abnormal fragmented prolonged low-frequency ventricular electrograms is performed by contact force catheter.
Trial Details
NCT Number NCT05643209
Lead Sponsor Maria Cecilia Hospital
Conditions Brugada Syndrome
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov